| Statistics |
Total online: 1 Guests: 1 Users: 0 |
|
Main » 2014 » January » 15
Analytical Tool - Lung Cancer is a
premium combo product of "Lung Cancer: A Decision Support Tool for
Optimizing the Pipeline from Research To Market" and "Lung Cancer
Drug Pipeline Update 2013". According to market analytical
studies, the therapeutic lung cancer drug market is predicted to exceed $4
billion between 2010 and 2015. Chemotherapy drugs will exp
...
Read more »
|
The launch of Protease inhibitors (PIs) created a wave in 2011-12 and
accelerated the pace of innovation and impressive Sustained Virologic Response
(SVR) rates by oral IFN free drug combinations have raised the bar and the
expectations of pts, physicians and investors. Freedom from IFN, treating all
genotypes and betting on vaccines could bring a sea of change in the HCV
therapy class area in the future. Roche set the trend with the acquisition of Anadys for total of $230m
followed by GILD buying VRUS for $11b, Bristol-Myers Squibb (BMY) acquired
Inhibitex for $2.5b, VRTX acquired Virochem in 2009 for $375m + in-licensed
Alios VX-135 in 2012 for total of $775m, and Abbott in-licensed
...
Read more »
| |
|
|
|
